Alnylam Pharmaceuticals | ALNY

Alnylam Pharmaceuticals traded at $201.24 this Tuesday October 4th, increasing $4.45 or 2.26 percent since the previous trading session. Looking back, over the last four weeks, Alnylam Pharmaceuticals gained 0.01 percent. Over the last 12 months, its price rose by 1.46 percent. Looking ahead, we forecast Alnylam Pharmaceuticals to be priced at 194.16 by the end of this quarter and at 177.20 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Takeda 3,846.00 -28.00 -0.72% 15.15%
Acadia Pharmaceuticals 18.06 1.02 5.99% 6.74%
Agios Pharmaceuticals 29.45 0.47 1.62% -32.96%
Alnylam Pharmaceuticals 201.24 4.45 2.26% 1.46%
Amgen 233.02 2.58 1.12% 9.99%
Arrowhead Research 34.91 1.17 3.47% -41.87%
Avrobio Inc 0.66 0.02 3.83% -87.65%
BioCryst Pharmaceuticals 14.07 1.27 9.92% 2.48%
Bluebird Bio 6.79 0.66 10.77% -62.84%
BioMarin Pharmaceutical 87.91 1.21 1.40% 14.57%
Intercept Pharmaceuticals 14.09 0.61 4.53% -2.29%
Incyte Corp 69.56 0.73 1.06% 6.47%
Ionis Pharmaceuticals 46.19 1.20 2.67% 40.87%
Moderna Inc 125.67 4.68 3.87% -62.16%
Mirati Therapeutics 67.99 -0.37 -0.54% -57.00%
Neurocrine Biosciences 109.24 2.52 2.36% 9.04%
Novartis 78.23 1.56 2.03% -4.40%
PTC Therapeutics 51.50 0.82 1.62% 41.02%
Ultragenyx Pharmaceutical 42.66 0.73 1.74% -51.03%
Regeneron Pharmaceuticals 739.54 4.41 0.60% 35.31%
Regulus Therapeutics 1.82 0.04 1.96% 178.07%
Sangamo BioSciences 5.07 0.29 6.07% -42.71%
Sanofi 40.12 0.93 2.37% -16.97%
Sarepta Therapeutics 111.47 1.53 1.39% 17.11%
Vertex Pharmaceuticals 300.64 3.21 1.08% 66.18%
Xencor 26.81 0.98 3.79% -25.09%

Indexes Price Day Year
USND 11176 360.97 3.34% -22.57%

Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.